Key result
Long-term dasatinib is linked to Takotsubo syndrome with rapid LVEF recovery within two days.
Why the study?
Takotsubo syndrome in cancer patients receiving long-term anticancer therapy presents diagnostic and therapeutic challenges due to multiple potential predisposing or triggering factors.
Case Report (n=1)
Takotsubo syndrome in patients on long-term dasatinib may involve a multifactorial substrate rather than a definitive drug-triggered cardiotoxicity, and can sometimes be managed without discontinuing the cancer therapy.
Answers are grounded in this paper and cite their sources.
May permit dasatinib continuation under surveillance after Takotsubo; leaves open causal link requiring larger studies.
Takotsubo syndrome (TTS) represents a diagnostic and therapeutic challenge in patients with cancer, in whom malignancy-related factors and anticancer therapies may coexist as potential predisposing or triggering factors. We report the case of a 68-year-old woman with chronic myeloid leukemia receiving dasatinib for two years who presented with acute heart failure. Initial echocardiography showed apical akinesia with a left ventricular ejection fraction of 38% and severely impaired global longitudinal strain (−6.3%). Coronary angiography revealed no significant obstructive coronary artery disease. Within two days, left ventricular function substantially improved, with an ejection fraction of 57% and global longitudinal strain of −14.2%. Cardiac magnetic resonance performed during this recovery phase demonstrated apical and mid-ventricular myocardial edema without late gadolinium enhancement, supporting the diagnosis of TTS. Although dasatinib-related myocardial and vascular effects provide biological plausibility for a potential contribution to TTS, a direct causal relationship could not be established. The long interval between treatment initiation and TTS onset, together with the coexistence of cancer-related predisposing factors, supports a multifactorial interpretation. Following multidisciplinary evaluation, dasatinib was continued under close cardiovascular monitoring. This case highlights that diagnostic certainty of TTS does not necessarily imply etiological certainty. In patients receiving long-term anticancer therapy, careful causal assessment is essential to distinguish a potential drug contribution from a multifactorial substrate and to avoid unnecessary discontinuation of effective cancer treatment.
No takes yet. Share an insight, caveat, or question.
Haddar et al. (2026) conducted a case report in Takotsubo Syndrome, Chronic Myeloid Leukemia (n=1). Dasatinib was evaluated. A 68-year-old woman developed Takotsubo syndrome after two years of dasatinib therapy, showing rapid left ventricular functional recovery with LVEF improving from 38% to 57% within two days.
Synapse has enriched 10 related papers. Consider them for comparative context: